IL1B and myocardial infarction: In both diabetic and non-diabetic rats with heart failure following a myocardial infarction, the administration of the anti-IL-1β antibody gevokizumab reduced the ventricular dimensions and improved its function (measured by echocardiography), decreasing hypertrophy and fibrosis [61].